Get the Latest Exas Stock Quote and Performance

Author

Reads 714

Hand Holding Smartphone with Stock Market Analysis Chart Dashboard Portfolio on Screen
Credit: pexels.com, Hand Holding Smartphone with Stock Market Analysis Chart Dashboard Portfolio on Screen

To get the latest EXAS stock quote and performance, you can visit the company's website or check online stock market platforms such as Yahoo Finance or Google Finance.

The EXAS stock price is listed on the NASDAQ stock exchange under the ticker symbol EXAS.

You can also check the company's financial statements and earnings reports to get a better understanding of its performance.

EXAS has reported significant revenue growth in recent years, with a 25% increase in 2020 compared to the previous year.

Related reading: Arlp Stock Quote

Stock Information

EXAS stock provides cancer screening and diagnostic test products in the United States and internationally.

The company's valuation is strong, with a Snowflake Score of 6/6.

Financial health is also a positive aspect, with a score of 4/6.

Here's a breakdown of the company's fundamental analysis scores:

Stock Overview

EXAS, a company that provides cancer screening and diagnostic test products in the United States and internationally.

EXAS fundamental analysis shows a mixed picture, with a Snowflake Score of 6/6 in valuation, indicating a good valuation, but only 4/6 in future growth, suggesting some uncertainty.

Some stocks, like Exelixis, have a good track record, while others, like Sarepta Therapeutics, may have some challenges ahead.

Here's a breakdown of the Snowflake Score components:

Exact Sciences Competitors

Credit: youtube.com, Citron's Left Calls Exact Sciences a 'Marketing Company'

Exact Sciences has a few major competitors in the genetic testing space.

LabCorp is a significant competitor, with a strong presence in the molecular diagnostics market. They offer a range of genetic testing services, including non-invasive prenatal testing (NIPT) and tumor profiling.

Invitae is another key competitor, known for its comprehensive genetic testing panels and affordable pricing. They also offer a range of genetic testing services, including cancer risk assessment and inherited disease testing.

Foundation Medicine is a leading provider of genomic testing solutions, with a focus on cancer treatment. Their tests help identify genetic mutations that can inform treatment decisions.

These competitors offer a range of genetic testing services that can be used for various purposes, including risk assessment, diagnosis, and treatment planning.

Performance Analysis

The current share price of EXAS is $55.41, with a 52-week high of $79.62 and a 52-week low of $40.62.

The stock has experienced a significant decline in recent months, with a 1-month change of -3.72% and a 3-month change of -21.36%. Over the past year, the stock has dropped by 15.64%.

Here are the key changes in EXAS stock price over the past 5 years:

In terms of shareholder returns, EXAS underperformed the US Biotechs industry, which returned -4.3% over the past year, and the US Market, which returned 22.7% over the same period.

Growth Rank

Credit: youtube.com, KPMG 2011 Performance Analysis - Fastest Revenue Growth

In the realm of performance analysis, growth rank is a crucial metric that helps investors gauge a company's potential for future growth.

The 3-Year Revenue Growth Rate stands at 12, indicating a steady increase in revenue over the past three years.

A 3-Year EPS without NRI Growth Rate of 29.7 suggests that the company's earnings per share have been growing at a rapid pace.

On the other hand, the 3-Year FCF Growth Rate of -27.9 indicates a decline in free cash flow, which could be a cause for concern.

The 3-Year Book Growth Rate of 7.3 suggests that the company's book value has been growing at a moderate pace.

Here's a snapshot of the growth rates:

This array of growth rates provides a comprehensive view of the company's growth trajectory, helping investors make informed decisions.

Momentum Rank

In the world of finance, momentum is a crucial factor in determining a stock's performance. The 5-Day RSI is currently at 54.54.

Credit: youtube.com, How to use Portfolio Maestro with momentum rank to achieve better results?

The 9-Day RSI is slightly lower at 49.34, indicating a more moderate pace. This difference in pace can be a sign of a stock's potential for growth or decline.

The 14-Day RSI is at 47.1, showing a more gradual trend. This can be an indicator of a stock's stability and consistency.

Here's a breakdown of the momentum percentages:

These numbers can give us a better understanding of a stock's momentum and potential for growth or decline.

GF Value Rank

The GF Value Rank is a key metric for evaluating a company's performance. It's calculated based on several key ratios, including the PS Ratio, which currently stands at 3.78.

The PS Ratio is a measure of how much investors are paying for each dollar of a company's sales. In this case, the PS Ratio is significantly higher than the industry average, indicating that the company may be overvalued.

The PB Ratio is another important metric, currently standing at 3.19. This ratio measures the price of the stock relative to its book value, and a lower ratio typically indicates a more undervalued stock.

Credit: youtube.com, Difference Between GF Value and Valuation Rank

The EV-to-FCF ratio is also worth noting, currently standing at 122.35. This ratio measures the price of the stock relative to its free cash flow, and a higher ratio typically indicates a more overvalued stock.

Here are some key GF Value Rank metrics:

These metrics provide a comprehensive view of the company's valuation and performance. By analyzing these ratios, investors can gain a better understanding of the company's potential for growth and profitability.

Price History & Performance

Let's take a closer look at the price history and performance of Exact Sciences. The current share price is a relatively stable US$55.41. The 52-week high is a significant US$79.62.

Over the past year, the stock has experienced a decline of 15.64%. This is a notable drop, especially considering the 3-year change of -28.41%. The 5-year change is even more dramatic, with a decrease of 43.08%.

Here's a summary of the stock's performance over different time periods:

The stock's beta of 1.24 indicates a moderate level of volatility. This means that the stock's price can be expected to move in tandem with the overall market, but with a slightly higher level of fluctuation.

Frequently Asked Questions

Is EXAS a good stock to buy?

According to analyst recommendations, 71.43% of experts strongly recommend buying EXAS, while 28.57% recommend it as a buy, indicating a generally positive sentiment. If you're considering investing in EXAS, it's worth exploring the reasons behind these recommendations.

Who are the largest shareholders of Exact Sciences?

The largest shareholders of Exact Sciences include The Vanguard Group, Inc., JPMorgan Investment Management, Inc., and SSgA Funds Management, Inc. These prominent investment firms hold significant stakes in the company.

Why is EXAS stock dropping?

EXAS stock is dropping primarily due to a significant decline in its Price to Sales Multiple (P/S). This unfavorable change has led to a 57% loss in value since the 2020 fiscal end.

Does EXAS pay a dividend?

No, Exact Sciences (EXAS) does not currently pay a dividend. As of December 13, 2024, the TTM dividend payout is $0.00.

Micheal Pagac

Senior Writer

Michael Pagac is a seasoned writer with a passion for storytelling and a keen eye for detail. With a background in research and journalism, he brings a unique perspective to his writing, tackling a wide range of topics with ease. Pagac's writing has been featured in various publications, covering topics such as travel and entertainment.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.